Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Industry: Healthcare

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline include XEN496, A Kv7 potassium channel modulator that is phase II clinical trials for the treatment of KCNQ2 epilepsy; XEN1101, A Kv7 potassium channel modulator, which is in phase II clinical trail for the treatment of epilepsy. The company's product candidates also comprise XEN901, a selective Nav1.6 sodium channel inhibitor that is in phase I clinical trials for the treatment of epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in phase I clinical trials. The company was founded in 1996 and is headquartered in Burnaby, Canada.

Current Quote*
Last: $9.850
Change: -0.020
Book: $3.001
Volume: 30,198

As Of: 05/24 13:15 ET
*Quotes delayed by 20min.

Graphs for XENE


3 Month Graph


6 Month Graph


1 Year Graph